← Back to Clinical Trials
Recruiting NCT06021275

NCT06021275 Microneedling With Regular Insulin Versus Microneedling Alone in Treatment of Atrophic Scars

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06021275
Status Recruiting
Phase
Sponsor Alexandria University
Condition Scars
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2023-10-01
Primary Completion 2024-12

Eligibility & Interventions

Sex All sexes
Min Age 12 Years
Max Age 60 Years
Study Type INTERVENTIONAL
All Conditions
Interventions
Microneedling with topical application of regular insulinMicroneedling with topical application of saline

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2023-10-01 with a primary completion date of 2024-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Recently, few studies have attempted to test the regenerative effects of human insulin application by microneedling on atrophic scars versus other topical preparations. However, the scars were limited etiologically to acne scars. In addition, a lack of inclusion of a control group instead of comparing topical preparations with insulin was also a limitation to these studies. A control group consisting of microneedling alone would have served as a better comparison in order to determine whether the effects of microneedling are augmented by topical protein-rich preparations.

Eligibility Criteria

Inclusion Criteria: 1. Patients aged 12 to 60 years 2. Atrophic scars (traumatic or surgical) 3. Completely healed scars Exclusion Criteria: 1. Patients with a tendency or history of hypertrophic or keloidal scars 2. Patients who received treatment for their scar in the past 3 months 3. Diabetic patients or those with a history of Dysglycemia 4. Pregnant, or lactating females 5. Patients with active infection at the site of scar 6. Patients currently receiving isotretinoin treatment or in the past month

Contact & Investigator

Central Contact

Dalia I Halwag, PhD, MD

✉ daliahalwag@gmail.com

📞 +00201224489473

Frequently Asked Questions

Who can join the NCT06021275 clinical trial?

This trial is open to participants of all sexes, aged 12 Years or older, up to 60 Years, studying Scars. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06021275 currently recruiting?

Yes, NCT06021275 is actively recruiting participants. Contact the research team at daliahalwag@gmail.com for enrollment information.

Where is the NCT06021275 trial being conducted?

This trial is being conducted at Alexandria, Egypt.

Who is sponsoring the NCT06021275 clinical trial?

NCT06021275 is sponsored by Alexandria University. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology